Literature DB >> 7738716

Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer.

P K Lipponen1.   

Abstract

Archival biopsy specimens from transitional cell bladder tumours (n = 185) were analysed immunohistochemically for expression of c-myc protein. The results were compared with histopathological and clinical parameters and survival. Forty-three per cent of the tumours were negative for c-myc protein and weak, moderate, or strong cytoplasmic expression was found in 34, 14, and 9 per cent of cases, respectively. Nuclear positivity for c-myc protein was detected in 35 per cent of tumours and nuclear positivity was related to overexpression of c-erb B-2 (P = 0.01) and a high proportion of nuclei were also positive for p53 oncoprotein (p < 0.05). Cytoplasmic expression of c-myc protein was related to histological grade (P = 0.005), papillary status (P = 0.007), the S-phase fraction (P = 0.008), the mitotic index (P = 0.021), overexpression of epidermal growth factor receptor (P = 0.045), and c-erb B-2 (P = 0.17). Expression of c-myc protein was not significantly related to the progression of tumours and it had no prognostic value in survival analysis. Independent predictors were the T-category (P < 0.001), papillary status. (P = 0.001), and S-phase fraction (P = 0.061). The results show that while c-myc gene product participates in growth regulation of human bladder cancer cells, it has no independent prognostic significance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7738716     DOI: 10.1002/path.1711750208

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  13 in total

1.  CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma.

Authors:  Yijun Xue; Gengqing Wu; Xiaoning Wang; Xiaofeng Zou; Guoxi Zhang; Rihai Xiao; Yuanhu Yuan; Dazhi Long; Jun Yang; Yuting Wu; Hui Xu; Folin Liu; Min Liu
Journal:  Med Oncol       Date:  2012-12-30       Impact factor: 3.064

2.  The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival.

Authors:  H J Okano; W Y Park; J P Corradi; R B Darnell
Journal:  Genes Dev       Date:  1999-08-15       Impact factor: 11.361

Review 3.  Molecular pathways in bladder cancer.

Authors:  Stephen G Williams; John P Stein
Journal:  Urol Res       Date:  2004-11-13

4.  Biomarkers in bladder cancer: present status and perspectives.

Authors:  Wun-Jae Kim; Soongang Park; Yong-June Kim
Journal:  Biomark Insights       Date:  2007-03-27

Review 5.  Molecular targets and targeted therapies in bladder cancer management.

Authors:  Ramy F Youssef; Anirban P Mitra; Georg Bartsch; Peter A Jones; Donald G Skinner; Richard J Cote
Journal:  World J Urol       Date:  2008-11-28       Impact factor: 4.226

6.  Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma.

Authors:  S Clasen; W A Schulz; C D Gerharz; M O Grimm; F Christoph; B J Schmitz-Dräger
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

7.  ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.

Authors:  Aya Kikuchi; Tomoyuki Suzuki; Taisuke Nakazawa; Masateru Iizuka; Ayako Nakayama; Tohru Ozawa; Minoru Kameda; Nobuaki Shindoh; Tadashi Terasaka; Masaaki Hirano; Sadao Kuromitsu
Journal:  Cancer Sci       Date:  2017-02       Impact factor: 6.716

8.  Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors.

Authors:  Ahmed S Abdulamir; Rand R Hafidh; Haider S Kadhim; Fatimah Abubakar
Journal:  J Exp Clin Cancer Res       Date:  2009-02-25

9.  E-cadherin involved in inactivation of WNT/beta-catenin signalling in urothelial carcinoma and normal urothelial cells.

Authors:  I Thievessen; H-H Seifert; S Swiatkowski; A R Florl; W A Schulz
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  Exploration of genetics commonness between bladder cancer and breast cancer based on a silcio analysis on disease subtypes.

Authors:  Wenbin Xu; Hong Xia; Wei Liu; Weiying Zheng; Lin Hua
Journal:  Technol Health Care       Date:  2018       Impact factor: 1.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.